Molecular and immune targets in cutaneous squamous cell carcinoma

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and often confers a good prognosis. Though surgery is the gold standard of treatment, unresectable or metastatic disease can necessitate systemic therapy. Of systemic agents, there is increasing interest in the use of immunotherapies and targeted therapy. Further study into the driver mutations in cSCC has identified opportunities for targeted therapy. In this review, we discuss both current and investigational immune and molecular targets of therapy for cSCC.

MicroRNA-124 plays an inhibitory role in cutaneous squamous cell carcinoma cells via targeting SNAI2, an immunotherapy determinant

“…Several signaling pathways regulate the progression of CSCC cells. However, proper targets in CSCC treatment are still to be identified [ 5 , 6 ]. Thus, exploring the molecular targets associated with CSCC and developing novel therapeutic strategies are urgently needed [ [7] , [8] , [9] ].…”